Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
77 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Liver Transplantation - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Liver Transplantation - Pipeline Review, H2 2014', provides an overview of the Liver Transplantation's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Liver Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Transplantation and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Liver Transplantation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Liver Transplantation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Liver Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Liver Transplantation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Liver Transplantation - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Liver Transplantation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Liver Transplantation Overview 7 Therapeutics Development 8 Pipeline Products for Liver Transplantation - Overview 8 Pipeline Products for Liver Transplantation - Comparative Analysis 9 Liver Transplantation - Therapeutics under Development by Companies 10 Liver Transplantation - Therapeutics under Investigation by Universities/Institutes 12 Liver Transplantation - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Liver Transplantation - Products under Development by Companies 16 Liver Transplantation - Products under Investigation by Universities/Institutes 17 Liver Transplantation - Companies Involved in Therapeutics Development 18 Astellas Pharma Inc. 18 Veloxis Pharmaceuticals A/S 19 Digna Biotech, S.L. 20 Conatus Pharmaceuticals Inc. 21 Dompe Farmaceutici S.p.A. 22 Isogenis, Inc. 23 Kings College London 24 Liver Transplantation - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 29 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 tacrolimus - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 tacrolimus ER - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 reparixin - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 emricasan - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Cell Therapy for Liver Transplantation - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Stem Cell Therapy for Immunology and Gastrointestinal Disorders - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 cardiotrophin-1 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Allogenic T regs - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Cell Therapy for Liver Transplantation - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 ABC-294640 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Liver Transplantation - Recent Pipeline Updates 54 Liver Transplantation - Dormant Projects 65 Liver Transplantation - Discontinued Products 66 Liver Transplantation - Product Development Milestones 67 Featured News & Press Releases 67 May 22, 2014: Veloxis Receives Positive Opinion from CHMP for Envarsus for Treatment of Both Kidney and Liver Transplant Patients 67 May 12, 2014: Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients 68 Apr 28, 2014: Veloxis Announces Scientific Publication of Phase II Study Demonstrating Conversion from Twice-Daily Tacrolimus to Once-Daily Envarsus in Liver Transplant Patients 68 Jan 08, 2014: Veloxis Pharmaceuticals Receives Notice of Allowance from U.S. Patent Office for Diurnal-Independent Administration of Envarsus 69 Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting 69 Sep 04, 2013: Phase III Clinical Study Data Demonstrating LCP-Tacro's Comparable Efficacy and Safety to Twice-Daily Tacrolimus Presented at the European Society for Organ Transplantation 70 Aug 22, 2013: Drug Application Filed for Additional Form of Immunosuppressant, "Cellcept Powder for Oral Suspension 32%" 72 Feb 15, 2013: Novartis's Zortress Receives FDA Approval To Prevent Organ Rejection In Adult Liver Transplant Patients 72 Dec 04, 2012: Astellas Pharma Announces Acceptance Of US New Drug Application For Tacrolimus Extended Release Capsules 73 Nov 12, 2012: Novartis Announces Positive Outcomes From Phase III Study Of Certican In Liver Transplantation 74 Appendix 76 Methodology 76 Coverage 76 Secondary Research 76 Primary Research 76 Expert Panel Validation 76 Contact Us 77 Disclaimer 77
List of Tables Number of Products under Development for Liver Transplantation, H2 2014 8 Number of Products under Development for Liver Transplantation - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Number of Products under Investigation by Universities/Institutes, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Products under Investigation by Universities/Institutes, H2 2014 17 Liver Transplantation - Pipeline by Astellas Pharma Inc., H2 2014 18 Liver Transplantation - Pipeline by Veloxis Pharmaceuticals A/S, H2 2014 19 Liver Transplantation - Pipeline by Digna Biotech, S.L., H2 2014 20 Liver Transplantation - Pipeline by Conatus Pharmaceuticals Inc., H2 2014 21 Liver Transplantation - Pipeline by Dompe Farmaceutici S.p.A., H2 2014 22 Liver Transplantation - Pipeline by Isogenis, Inc., H2 2014 23 Liver Transplantation - Pipeline by Kings College London, H2 2014 24 Assessment by Monotherapy Products, H2 2014 25 Number of Products by Stage and Target, H2 2014 28 Number of Products by Stage and Mechanism of Action, H2 2014 31 Number of Products by Stage and Route of Administration, H2 2014 33 Number of Products by Stage and Molecule Type, H2 2014 35 Liver Transplantation Therapeutics - Recent Pipeline Updates, H2 2014 54 Liver Transplantation - Dormant Projects, H2 2014 65 Liver Transplantation - Discontinued Products, H2 2014 66
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.